Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 265

The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.

Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma

Open access
Nayak, Lakshmi, Molinaro, Annette M., Peters, Katherine, Clarke, Jennifer L., Jordan, Justin T., de Groot, John, Nghiemphu, Leia, Kaley, Thomas, Colman, Howard, McCluskey, Christine, Gaffey, Sarah, Smith, Timothy R., Cote, David J., Severgnini, Mariano, Yearley, Jennifer H., Zhao, Qing, Blumenschein, Wendy M., Duda, Dan G., Muzikansky, Alona, Jain, Rakesh K., Wen, Patrick Y., Reardon, David A.·2021·Clinical Cancer Research

Abstract

Purpose: VEGF is upregulated in glioblastoma and may contribute to immunosuppression. We performed a phase II study of pembrolizumab alone or with bevacizumab in recurrent glioblastoma. Patients and Methods: Eighty bevacizumab-naïve patients with recurrent glioblastoma were randomized to pembrolizumab with bevacizumab (cohort A, n = 50) or pembrolizumab monotherapy (cohort B, n = 30). The primary endpoint was 6-month progression-free survival (PFS-6). Assessed biomarkers included evaluation of tumor programmed death-ligand 1 expression, tumor-infiltrating lymphocyte density, immune activation gene expression signature, and plasma cytokines. The neurologic assessment in neuro-oncology (NANO) scale was used to prospectively assess neurologic function. Results: Pembrolizumab alone or with bevacizumab was well tolerated but of limited benefit. For cohort A, PFS-6 was 26.0% [95% confidence interval (CI), 16.3–41.5], median overall survival (OS) was 8.8 months (95% CI, 7.7–14.2), objective response rate (ORR) was 20%, and median duration of response was 48 weeks. For cohort B, PFS-6 was 6.7% (95% CI, 1.7–25.4), median OS was 10.3 months (95% CI, 8.5–12.5), and ORR was 0%. Tumor immune markers were not associated with OS, but worsened OS correlated with baseline dexamethasone use and increased posttherapy plasma VEGF (cohort A) and mutant IDH1, unmethylated MGMT, and increased baseline PlGF and sVEGFR1 levels (cohort B). The NANO scale contributed to overall outcome assessment. Conclusions: Pembrolizumab was ineffective as monotherapy and with bevacizumab for recurrent glioblastoma. The infrequent radiographic responses to combinatorial therapy were durable. Tumor immune biomarkers did not predict outcome. Baseline dexamethasone use and tumor MGMT warrant further study as potential biomarkers in glioblastoma immunotherapy trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-20-2500

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 58 references

Cited by

See all 265

Metadata

Authors
Nayak, L., Molinaro, A. M., Peters, K., Clarke, J. L., Jordan, J. T., de Groot, J., Nghiemphu, L., Kaley, T., Colman, H., McCluskey, C., Gaffey, S., Smith, T. R., Cote, D. J., Severgnini, M., Yearley, J. H., Zhao, Q., Blumenschein, W. M., Duda, D. G., Muzikansky, A., Jain, R. K., Wen, P. Y., & Reardon, D. A.
Venue
Clinical Cancer Research
Published
2021-02-15
Volume
27
Issue
4
Pages
1048-1057
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W3099035428
Cited by
265
References
58
FWCI
13.33
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-20-2500
The paper
Nayak, L., Molinaro, A. M., Peters, K., Clarke, J. L., Jordan, J. T., de Groot, J., Nghiemphu, L., Kaley, T., Colman, H., McCluskey, C., Gaffey, S., Smith, T. R., Cote, D. J., Severgnini, M., Yearley, J. H., Zhao, Q., Blumenschein, W. M., Duda, D. G., Muzikansky, A., . . . Reardon, D. A. (2021). Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-20-2500

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.